as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹503.95
Change
-2.45 (-0.48%)
Open
₹509.95
Prev. Close
₹506.4
Day High
₹510.95
Day Low
₹502.1
Volume Analysis
Traded
29,566
Delivered
18,464
Delivery %
62.45%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (2)
- •Low return on equity (4.88%)
- •Below-average fundamentals quality score (42/100)
Opportunities (1)
- •Strong 3-year revenue growth (57.8%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹518.09 | ₹514.52 | ₹509.24 | ₹505.67 | ₹500.39 | ₹496.82 | ₹491.54 |
| Fibonacci | ₹514.52 | ₹511.14 | ₹509.05 | ₹505.67 | ₹502.29 | ₹500.2 | ₹496.82 |
| Camarilla | ₹506.38 | ₹505.57 | ₹504.76 | ₹505.67 | ₹503.14 | ₹502.33 | ₹501.52 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-1.35%
1 Month
-3.34%
3 Months
-14.35%
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
2.87%
Net margin 3.67% × asset turnover 0.27x × equity multiplier 2.9x
Company Overview
Sector
Healthcare
Market Cap
₹2,226 Cr
P/E (TTM)
107.0
ROE
4.88%
Face Value
₹5.0
Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.
TopFund Analysis
Sai Parenterals Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 42/100. The strongest factor is Risk & Volatility (81/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (4.88%); below-average fundamentals quality score (42/100). FII holding has been falling.
TopFund Score — Fundamentals Quality
42/100 — WeakData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Debtor days have improved from 253 to 173 days.
- −Company has low interest coverage ratio.
- −Company has a low return on equity of 8.64% over last 3 years.
- −Company might be capitalizing the interest cost
- −Company has high debtors of 173 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Sai Parenterals’ 10 Sep 2026 AGM resolutions, including director reappointments and secretarial auditor appointment, passed.
25th AGM held on 10 Sep 2026; 12 resolutions passed, including IPO proceeds variation and management appointments.
Subsidiary renewed 3-year OTC supply deal with Australian pharmacy chain worth AUD 30 million (~Rs204 crore).
Noumed renewed a 3-year OTC supply deal with an Australian pharmacy chain, worth AUD 30 million.
Intimation of schedule of Analyst/Institutional Investors Meeting scheduled to be held on 31st August, 2026
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales + | 33 | 96 | 198 | 179 |
| Expenses + | 29 | 100 | 172 | 155 |
| Operating Profit | 5 | -4 | 26 | 24 |
| OPM % | 14.2% | -3.7% | 13.19% | 13.16% |
| Other Income + | 1 | 3 | 3 | 4 |
| Interest | 2 | 5 | 8 | 9 |
| Depreciation | 1 | 6 | 8 | 8 |
| Profit before tax | 2 | -12 | 12 | 10 |
| Tax % | 29.5% | -42.65% | -6.13% | 19.0% |
| Net Profit + | 1 | -7 | 13 | 8 |
| EPS in Rs | 1 | -2 | 3 | 2 |
| Raw PDF | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales + | 97 | 154 | 163 | 381 |
| Expenses + | 78 | 122 | 124 | 342 |
| Operating Profit | 19 | 32 | 39 | 39 |
| OPM % | 19.0% | 21.0% | 24.0% | 10.0% |
| Other Income + | 0 | 1 | 1 | 9 |
| Interest | 6 | 11 | 12 | 19 |
| Depreciation | 6 | 9 | 8 | 17 |
| Profit before tax | 7 | 13 | 20 | 12 |
| Tax % | 40.0% | 33.0% | 28.0% | -20.0% |
| Net Profit + | 4 | 8 | 14 | 14 |
| EPS in Rs | 6 | 6 | 5 | 3 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Reserves | 24 | 61 | 80 | 469 |
| Borrowings + | 69 | 119 | 94 | 469 |
| Other Liabilities + | 34 | 75 | 85 | 465 |
| Total Liabilities | 134 | 268 | 272 | 1,424 |
| Fixed Assets + | 44 | 70 | 53 | 364 |
| CWIP | 2 | 0 | 0 | 212 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets + | 88 | 198 | 219 | 848 |
| Total Assets | 134 | 268 | 272 | 1,424 |
| Equity Capital | 7 | 13 | 13 | 22 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | -13 | -30 | 33 | 93 |
| Cash from Investing Activity + | -19 | -46 | 0 | -274 |
| Cash from Financing Activity + | 24 | 79 | -36 | 596 |
| Net Cash Flow | -8 | 2 | -2 | 415 |
| CFO/OP | -54 | -94 | 86 | 253 |
| Free Cash Flow | -30 | -72 | 41 | -184 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Mar 2026 | Jun 2026 | |
|---|---|---|
| Public | 30.25% | 36.29% |
| Promoters | 51.16% | 51.16% |
| FII | 5.73% | 4.03% |
| DII | 12.86% | 8.52% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Sai Parenterals Limited (this stock) | 2,226 | 107.0 | — | 4.88% |
| Venus Remedies Limited | 2,230 | 19.2 | 3.36 | 16.8% |
| Windlas Biotech Limited | 2,275 | 34.2 | 4.01 | 12.2% |
| Panacea Biotec Ltd | 2,282 | — | 2.74 | -2.42% |
| Fredun Pharmaceuticals L | 2,305 | 52.6 | 8.2 | 15.6% |
| Indoco Remedies Ltd. | 2,306 | — | 2.45 | -9.36% |
| Beta Drugs Limited | 2,400 | 52.6 | 8.98 | 18.8% |
Which Mutual Funds Hold Sai Parenterals Limited?
Frequently Asked Questions about Sai Parenterals Limited
Sai Parenterals Limited (SAIPARENT) closed at ₹503.95 on NSE on 25 September 2026, down 2.45 (0.48%) from the previous close.
Sai Parenterals Limited trades on the NSE (National Stock Exchange of India) under the symbol SAIPARENT.
Sai Parenterals Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 107.0.
Sai Parenterals Limited has a dividend yield of 0.0%.
Sai Parenterals Limited's 52-week high is ₹706.0 and its 52-week low is ₹400.0.
Sai Parenterals Limited has a market capitalisation of ₹2,226 crore.
Sai Parenterals Limited has a TopFund Quality Score of 42/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Sai Parenterals Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.